Scrutinizer Report and Voting Results for the AGM held on 30.09.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fredun Pharmaceuticals held its 38th Annual General Meeting on September 30, 2025 via video conferencing, where all 8 resolutions were passed with 100% votes in favor and zero votes against. Shareholders approved the audited financial statements for FY ending March 31, 2025 and declared a 7% dividend on equity shares for the same year. Mr. Fredun Nariman Medhora was re-appointed as Managing Director (retiring by rotation), and the remuneration of the Cost Auditor for FY2026 was ratified. Two new Non-Executive Independent Directors were appointed — Mr. Anshu Agarwal and Ms. Sonal Dharmin Desai — and Ms. Kala Agarwal was appointed as Secretarial Auditor for a five-year term. A Special Resolution was also passed approving transactions with related parties. Voting turnout was low, with only about 22% of outstanding shares (10.4 lakh out of 47.2 lakh shares) being polled by 68 members; no public institutional shareholders participated in the voting.
The 7% dividend is a small but tangible return for shareholders, and the clean unanimous approval of all resolutions indicates no governance friction, though the very low public voting turnout (especially zero participation from institutions) signals limited institutional interest or engagement in this small-cap stock.